Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16179448 | 0.84 | MRGPRX4 (0.42) | ARTRPV4AKR1C3PDE4APDE4C | |
| SCHEMBL21723413 | 0.82 | SLC22A12 (0.41) | ACLYTRPV4STSCYP19A1AKR1C3 | |
| SCHEMBL31245789 | 0.82 | SLC22A12 (0.41) | ACLYTRPV4STSCYP19A1AKR1C3 | |
| SCHEMBL5728291 | 0.82 | EPAS1 (0.45) | TRPV4STSCYP19A1AKR1C3PDE4A | |
| SCHEMBL7337197 | 0.81 | PDE4A (0.38) | ARACLYALPLAKR1C3PDE4A | |
| SCHEMBL14537815 | 0.81 | CA12 (0.43) | ARACLYALPLSTS | |
| SCHEMBL1738137 | 0.81 | TRPV4 (0.54) | TRPV4AKR1C3PDE4APDE4CPDE4D | |
| SCHEMBL3363775 | 0.81 | AR (0.44) | ARTRPV4STSCYP19A1PDE4A | |
| SCHEMBL16962986 | 0.80 | PTGDR2 (0.41) | TRPV4AKR1C3PDE4APDE4CPDE4D | |
| SCHEMBL16784589 | 0.79 | AR (0.48) | ARACLYALPLTRPV4STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| US-RE49575-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-07-11 | — | — | US | disclosed |
| US-RE49575-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-07-11 | — | — | US | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| US-10399977-B2 | Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-03 | — | — | US | disclosed |
| US-10392384-B2 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10336749-B2 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20190127369-A1 | Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient | Bayer Pharma AG (DE) | 2019-05-02 | — | — | US | disclosed |
| WO-2007140894-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140894-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1539749-A4 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7105533-B2 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539749-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024074-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399977-B2 | Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient | CYP4B1, CYP2S1, CYP3A4 | AR 4194/4885ACLY 2131/4885ALPL 2160/4885 |
| US-10392384-B2 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods | MT-ND4, ENTPD1, COX4I1 | AR 4506/4885ACLY 861/4885ALPL 1834/4885 |
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | GRM5, GRIK5, GRM1 | AR 3131/4885ACLY 3180/4885ALPL 3934/4885 |
| US-10336749-B2 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | CYP4B1, CYP2D6, QDPR | AR 3919/4885ACLY 833/4885ALPL 1659/4885 |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | AR 653/4885ACLY 1997/4885ALPL 4290/4885 |
| US-20190127369-A1 | Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient | CYP4B1, CYP2S1, CYP3A4 | AR 4194/4885ACLY 2131/4885ALPL 2160/4885 |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | AR 229/4885ACLY 1588/4885ALPL 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.